title: [Sclerosing cholangitis as a complication of Langerhans'cell histiocytosis].
abstract: BACKGROUND
  Langerhans'cell histiocytosis is a rare and mainly pediatric disease. Patients with hepatic involvement usually have a disseminated form of the disease, with poor prognosis. Sclerosing cholangitis can occur in 10 to 15% of multivisceral Langerhans'cell histiocytosis. We report the case of a 56-years-old patient who developed sclerosing cholangitis 12 years after the diagnosis of Langerhans'cell histiocytosis.
  
  
  METHODS
  A 56-years-old man was admitted because of rapid general health impairment with epigastric pain. He was diagnosed as having Langerhans'cell histiocytosis 12 years ago because of a diabetes insipidus. Lungs were involved and during follow-up vertebral osteocondensation also developed. However, Langerhans'cell histiocytosis was clinically silent at the time of admission, without any treatment. Biologically, cholestasis and inflammation were noted. Digestive radiological investigations (echo-endoscopy, CT-scan, MRI) showed homogenous hepatomegaly and a diffuse infiltration of intra and extrahepatic bile ducts. Liver biopsy yielded the diagnosis of sclerosing cholangitis. Clinical and biological improvement occurred with oral corticosteroids (at 12 months after sclerosing cholangitis diagnosis).
  
  
  CONCLUSIONS
  Sclerosing cholangitis is a potential complication of Langerhans'cell histiocytosis, mainly in its multivisceral form. It can occur at a median of 2 years after diagnosis in children, but occasionally much later in adults, whereas Langerhans'cell histiocytosis seems quiescent. Diagnosis is supported by radiological investigations and liver biopsy. As no drug therapy appears clearly effective, liver transplantation must frequently be considered in these patients.
authors.affiliation: Service de rhumatologie, groupe hospitalier Bichat-Claude-Bernard, 46, rue Henri-Huchard, 75877 Paris cedex 18, France.
authors.forename: C
authors.initials: C
authors.lastname: Pagnoux
authors.forename: G
authors.initials: G
authors.lastname: Hayem
authors.forename: F
authors.initials: F
authors.lastname: Roux
authors.forename: E
authors.initials: E
authors.lastname: Palazzo
authors.forename: O
authors.initials: O
authors.lastname: Meyer
mesh_terms: D015746:Abdominal Pain / Q000209:etiology; D000367:Age Factors; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001707:Biopsy, Needle; D002756:Cholagogues and Choleretics / Q000627:therapeutic use; D002760:Cholangiopancreatography, Endoscopic Retrograde; D015209:Cholangitis, Sclerosing / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology*; D003919:Diabetes Insipidus / Q000209:etiology; D018450:Disease Progression; D004359:Drug Therapy, Combination; D019160:Endosonography; D006646:Histiocytosis, Langerhans-Cell / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D035583:Rare Diseases; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use; D015431:Weight Loss
chemical_list: D000893:Anti-Inflammatory Agents; D002756:Cholagogues and Choleretics; D014580:Ursodeoxycholic Acid; D011241:Prednisone